TOP MS
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Glatiramer acetate
Unknown
What it measured
Main measures
Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes
12 months and 24 months
Other measures (1)
Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes
12 months and 24 months
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 and over
Inclusion Criteria: * Male or female, 18 years of age or older, with a diagnosis of MS. * Being treated with Glatiramer Acetate (GA) or (IFN)-β * Receiving therapy from a participating Specialty Pharmacy Exclusion Criteria: * Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study * Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP) * Unlikely to be able to participate for the full two years of the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
Papers
Results
Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord. 2015 Jan;4(1):75-82. doi: 10.1016/j.msard.2014.09.214. Epub 2014 Oct 7.Results
Coyle PK, Cohen BA, Leist T, Markowitz C, Oleen-Burkey M, Schwartz M, Tullman MJ, Zwibel H. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol. 2014 Mar 13;14:49. doi: 10.1186/1471-2377-14-49.
Loading reviews and guidelines…
Related trials
- CPE
Completed
No result found
- Copaxone Subcutaneous Injection Syringe Special Drug Use-…
Completed
No result found
- Long Term Safety of Teriflunomide When Added to Interfero…
Phase 2 · Completed
Main goal was not benefit
- Phase II Study of Teriflunomide as Adjunctive Therapy to …
Phase 2 · Completed
Main goal was not benefit
History
Started
Dec 2008
Main results due
Dec 2012
Finished
Jan 2013
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error